2024
Prediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy
Arcos D, Ng D, Ke Y, Toh Y, Chan A. Prediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy. Supportive Care In Cancer 2024, 32: 76. PMID: 38170327, PMCID: PMC10764400, DOI: 10.1007/s00520-023-08274-5.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancer patientsBreast cancer patientsTreatment of Cancer Quality of Life QuestionnaireCancer Quality of Life QuestionnaireCancer patientsFemale breast cancer patientsQuality of Life QuestionnaireEORTC QLQ-C30European Organisation for ResearchProspective cohort studyQuality of lifeSymptom progressionGI symptomsQLQ-C30Life QuestionnaireSecondary analysisSymptom trajectoriesCohort studyResultsThe analysisInferential statisticsBaseline inflammatory markersAppetite lossInflammatory biomarkersSymptomsBaseline
2023
Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults — United States, December 2020–March 2023
Montoy J, Ford J, Yu H, Gottlieb M, Morse D, Santangelo M, O’Laughlin K, Schaeffer K, Logan P, Rising K, Hill M, Wisk L, Salah W, Idris A, Huebinger R, Spatz E, Rodriguez R, Klabbers R, Gatling K, Wang R, Elmore J, McDonald S, Stephens K, Weinstein R, Venkatesh A, Saydah S, Group I, Group I, Ahmed Z, Choi M, Derden A, Gottlieb M, Guzman D, Hassaballa M, Jerger R, Kaadan M, Koo K, Yang G, Dorney J, Kinsman J, Li S, Lin Z, Mannan I, Pierce S, Puente X, Ulrich A, Yang Z, Yu H, Adams K, Anderson J, Chang G, Gentile N, Geyer R, Maat Z, Malone K, Nichol G, Park J, Ruiz L, Schiffgens M, Stober T, Willis M, Zhang Z, Amadio G, Charlton A, Cheng D, Grau D, Hannikainen P, Kean E, Kelly M, Miao J, Renzi N, Shughart H, Shughart L, Shutty C, Watts P, Kane A, Nikonowicz P, Sapp S, Gallegos D, Martin R, Chandler C, Eguchi M, L’Hommedieu M, Moreno R, Roldan K, Arreguin M, Chan V, Chavez C, Kemball R, Wong A, Briggs-Hagen M, Hall A, Plumb I. Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults — United States, December 2020–March 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 859-865. PMID: 37561663, PMCID: PMC10415002, DOI: 10.15585/mmwr.mm7232a2.Peer-Reviewed Original ResearchConceptsCOVID-like illnessSARS-CoV-2 test resultsPost-COVID conditionsNegative SARS-CoV-2 test resultsPositive SARS-CoV-2 test resultProspective multicenter cohort studySARS-CoV-2 infectionMulticenter cohort studyPrevalence of symptomsTime of enrollmentCOVID-19 testing statusHealth care providersSARS-CoV-2Self-reported symptomsCohort studyPersistent symptomsAcute illnessAntigen testPolymerase chain reactionClinical signsSymptom progressionCare providersDrug AdministrationTesting statusSymptomsInflammatory and interferon gene expression signatures in patients with mitochondrial disease
Warren E, Gordon-Lipkin E, Cheung F, Chen J, Mukherjee A, Apps R, Tsang J, Jetmore J, Schlein M, Kruk S, Lei Y, West A, McGuire P. Inflammatory and interferon gene expression signatures in patients with mitochondrial disease. Journal Of Translational Medicine 2023, 21: 331. PMID: 37208779, PMCID: PMC10199642, DOI: 10.1186/s12967-023-04180-w.Peer-Reviewed Original ResearchConceptsMTD patientsHealthy controlsMitochondrial dysfunctionAntiviral responseInterferon gene expression signatureChronic inflammatory disordersType I interferonCommon gene signaturePeripheral inflammationGene expression signaturesImmune dysregulationChronic inflammationMetabolic decompensationInflammatory disordersInterleukin-1βSymptom progressionT cellsInflammatory signalingMouse modelI interferonMitochondrial diseasePatientsTranslational evidenceMELAS patientsDysfunctionDoes polygenic risk for substance‐related traits predict ages of onset and progression of symptoms?
Kranzler H, Feinn R, Xu H, Ho B, Saini D, Nicastro O, Jacoby A, Toikumo S, Gelernter J, Hartwell E, Kember R. Does polygenic risk for substance‐related traits predict ages of onset and progression of symptoms? Addiction 2023, 118: 1675-1686. PMID: 37069489, PMCID: PMC10525011, DOI: 10.1111/add.16210.Peer-Reviewed Original ResearchConceptsOpioid use disorderSubstance use disordersProgression of symptomsPolygenic risk scoresAlcohol use disorderUse disordersAfrican ancestry individualsGenetic riskRegular useEuropean ancestry individualsEarly onsetMore rapid progressionRegular alcohol useShorter progression timeAge of onsetFirst substance useDiscovery sampleUS inpatientsOnset of problemsOutpatient settingDisease progressionRapid progressionSymptom progressionRisk scoreGenome-wide association studies
2012
A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis
Shields SD, Cheng X, Gasser A, Saab CY, Tyrrell L, Eastman EM, Iwata M, Zwinger PJ, Black JA, Dib‐Hajj S, Waxman SG. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Annals Of Neurology 2012, 71: 186-194. PMID: 22367990, DOI: 10.1002/ana.22665.Peer-Reviewed Original ResearchConceptsMultiple sclerosisCerebellar dysfunctionMouse modelPurkinje neuronsNervous systemNew transgenic mouse modelPurkinje neuron firingDisease-modifying agentsSodium channel Nav1.8Healthy nervous systemPeripheral nervous systemTransgenic mouse modelCerebellar Purkinje neuronsWild-type littermatesNav1.8 expressionNeurons altersSymptom burdenSymptomatic therapySymptom progressionNav1.8Electrophysiological propertiesNeuron firingDysfunctionEAEMotor behavior
2005
1639: Development of a Nomogram to Predict Symptom Progression with or without Medical Therapy in Men with BPH Based on Data from the MTOPS Trial
Slawin K, Roehrborn C, McConnell J, Kreder K, Jacobs S, McVary K, Foster H, Clarke H, Milam D, Noble W, Nyberg L, Kusek J, Kattan M. 1639: Development of a Nomogram to Predict Symptom Progression with or without Medical Therapy in Men with BPH Based on Data from the MTOPS Trial. Journal Of Urology 2005, 173: 444. DOI: 10.1016/s0022-5347(18)35761-6.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply